AstraZeneca (LON:AZN) Given “Buy” Rating at Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Berenberg Bank in a note issued to investors on Wednesday, Digital Look reports. They currently have a £175 price target on the biopharmaceutical company’s stock. Berenberg Bank’s price objective suggests a potential upside of 45.86% from the stock’s current price.

Several other analysts have also recently weighed in on AZN. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £117 price target on shares of AstraZeneca in a report on Tuesday, September 29th. Royal Bank Of Canada reiterated an “outperform” rating and issued a £145 target price on shares of AstraZeneca in a report on Tuesday, September 8th. Citigroup raised their price target on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a £175 price target on shares of AstraZeneca in a research report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Stock Performance

LON:AZN opened at £119.98 on Wednesday. The company has a market cap of £186.08 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 0.86 and a beta of 0.20. The stock has a fifty day moving average price of £120.45 and a 200-day moving average price of £131.98. AstraZeneca has a fifty-two week low of £114.04 and a fifty-two week high of £157.32. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89.

Insider Buying and Selling at AstraZeneca

In other news, insider Michel Demare purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average price of £121.21 per share, for a total transaction of £303,025. Corporate insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.